
João Melo Beirão

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1745433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema. Ophthalmic Research, 2022, 65, 310-320.	1.0	2
2	Corneal Biomechanics for Ocular Hypertension, Primary Open-Angle Glaucoma, and Amyloidotic Glaucoma: A Comparative Study by Corvis ST. Clinical Ophthalmology, 2022, Volume 16, 71-83.	0.9	10
3	CHOROIDAL INVOLVEMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS PATIENTS. Retina, 2022, 42, 775-781.	1.0	3
4	Inverted internal limiting membrane flap technique in the surgical treatment of macular holes: 8-year experience. International Ophthalmology, 2021, 41, 499-507.	0.6	5
5	Dealing with rhegmatogenous retinal detachment in patients under 40Âyears old: a tertiary center results. International Ophthalmology, 2021, 41, 475-482.	0.6	4
6	Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis – assessed with optical coherence tomography angiography. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 66-71.	1.4	8
7	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology, 2021, 268, 2109-2122.	1.8	141
8	Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant. Ophthalmic Research, 2021, 64, 639-647.	1.0	4
9	Epiretinal membrane vitrectomy: outcomes with or without cataract surgery and a novel prognostic factor for cystoid macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1731-1740.	1.0	4
10	Pupillometry: An objective test to assess endocular hereditary transthyretin amyloidosis. European Journal of Ophthalmology, 2021, , 112067212199729.	0.7	5
11	Ahmed valve for secondary glaucoma in patients with hereditary transthyretin amyloidosis. Eye, 2021, , \cdot	1.1	8
12	Corneal Biomechanical Assessment with Ultra-High-Speed Scheimpflug Imaging During Non-Contact Tonometry: A Prospective Review. Clinical Ophthalmology, 2021, Volume 15, 1409-1423.	0.9	5
13	Response to the letter "Comments on â€~Pupillometry: An objective test to assess endocular hereditary transthyretin amyloidosis'â€; by Shinji Kakihara, Takao Hirano, Akira Imai, Teruyoshi Miyahara and Toshinori Murata. European Journal of Ophthalmology, 2021, , 112067212110280.	0.7	0
14	Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 275-276.	1.4	3
15	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
16	A 15-year retrospective epidemiologic study of ocular trauma in the north of Portugal. European Journal of Ophthalmology, 2020, 31, 112067212093439.	0.7	10
17	Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 77-78.	1.4	1
18	Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Ophthalmic Research, 2018, 59, 68-75.	1.0	41

JOãO MELO BEIRãO

#	Article	IF	CITATIONS
19	Anterior Chamber Flare as an Objective and Quantitative Noninvasive Method for Oculopathy in Transthyretin V30M Amyloidosis Patients. Journal of Ophthalmology, 2018, 2018, 1-5.	0.6	о
20	<i>Tafamidis</i> in hereditary ATTR amyloidosis – our experience on monitoring the ocular manifestations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 262-263.	1.4	13
21	Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2015. 22. 93-99.	1.4	7
22	Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 31-35.	1.4	32
23	Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 117-122.	1.4	71
24	Spatial visual contrast sensitivity in liver transplanted Portuguese familial amyloidotic polyneuropathy (ATTR V30M) patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 152-155.	1.4	8
25	No ocular involvement in familial amyloidotic polyneuropathy ATTR V30M domino liver recipients. Transplant International, 2012, 25, 646-651.	0.8	9
26	Anticipation of presbyopia in Portuguese familial amyloidosis ATTR V30M. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 92-97.	1.4	9
27	Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives. Clinical Ophthalmology, 0, Volume 16, 2227-2233.	0.9	2